Why Don't Targeted Drugs Always Work? The Answer Lies in Your Genetic Code
In this article
Genetic Blind Spots and a New Discovery in Treatment Resistance
Why Does It Matter?
Monoclonal antibodies, often described as smart drugs, have revolutionized cancer treatment over the past 20 years. Rituximab, trastuzumab and daratumumab have saved millions of lives. Yet clinicians frequently encounter a scenario that leaves physicians and patients feeling helpless: "On paper, this drug should work for this patient, but it doesn't."
Until now, we usually attributed this to tumor resistance or unknown factors. However, a groundbreaking study by University of Basel researchers in Science Translational Medicine (17 December 2025) identified a more fundamental cause: a microscopic mismatch in the patient's own genetic code .
This study could fundamentally change personalized treatment in medical oncology. It demonstrates that we need to examine patients' genetics as well as tumor genetics, because even a single-letter change can disable a powerful drug. This article explores the discovery and how it may shape future treatment.
The Lock-and-Key Match: What Can One Letter Change?
Targeted drugs are designed to fit their targets (antigens) precisely. Dr. Lukas Jeker and colleagues at the University of Basel discovered that this precision can become a weakness: "If a target protein has a mutation exactly where the antibody should bind, the antibody can no longer attach and loses its effect."
Scenario A: Standard Genetics (Compatible)
Patient: Standard genetic sequence (Wild Type).
Drug: Monoclonal antibody (key).
Target: Protein on the cancer cell (lock).
Result: The key fits perfectly. The drug attaches and activates the immune system. ✓ The Drug Works; the Cancer Cell Dies.
Scenario B: A Single Amino Acid Change (Incompatible)
Patient: A small inherited genetic variation is present.
Problem: This variation microscopically changes the shape of the lock, the target protein on the cancer cell.
Result: The drug is unchanged, but no longer fits. It circulates in the blood without binding its target. ✕ Treatment Fails.
Clinical Evidence: Which Drugs Are at Risk?
Researchers screened all therapeutic antibodies recognized by the World Health Organization and their targets in the Protein Data Bank. The findings identified this risk for many drugs commonly used in oncology, hematology and neurology. The most striking examples follow:
- 1. Rituximab (Lymphoma and Leukemia Treatment):
This drug targets CD20, but in patients carrying variants in the MS4A1 gene, single nucleotide changes can prevent antibody binding. As a result, B cells cannot be eliminated.
Is There a Solution? Yes. Laboratory tests showed that variants resistant to rituximab binding could still bind Ofatumumab, another drug against the same target. Switching drugs could therefore save lives. - 2. Daratumumab (Multiple Myeloma):
This CD38-targeting drug may be ineffective in patients carrying a genetic variant. However, the alternative drug Isatuximab is unaffected by that variant, highlighting the role of genetics in treatment selection.
- 3. HER2 Drugs (Breast Cancer):
Even potent antibody-drug conjugates (ADCs) used in breast cancer cannot bind the tumor when HER2 carries a specific variant such as P594H , rendering them ineffective. The problem lies in the target's changed shape rather than the drug's potency.
A Future Vision: A Genetic Identity Check Before Treatment
Senior authors Dr. Rosalba Lepore and Dr. Lukas Jeker note that no standard clinical test currently detects these variants, although the technology is ready. Standard sequencing methods can identify them easily.
- Test Result: "The patient carries a rituximab-resistant variant."
- Physician's Decision: "Then we will start directly with ofatumumab."
- Result: Months of unsuccessful treatment, lost time and unnecessary costs could be avoided.
- Marone R, Asllanaj E, Capoferri G, et al. Single–amino acid variants in target epitopes can confer resistance to antibody-based therapies. Science Translational Medicine. 2025 Dec 17;17(829). doi:10.1126/scitranslmed.ady4877
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.